Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Journal
The lancet. Gastroenterology & hepatology
Journal Volume
8
Journal Issue
3
Pages
228-241
Date Issued
2023-03
Author(s)
Jiang, Xiao-Tao
Luo, Jiing-Chyuan
Bair, Ming-Jong
Chen, Po-Yueh
Chou, Chu-Kuang
Lee, Ji-Yuh
Yang, Tsung-Hua
Yu, Chien-Chun
Kuo, Chia-Chi
Chiu, Min-Chin
Chen, Chi-Yi
Tsai, Min-Horn
Hsu, Yao-Chun
Tseng, Cheng-Hao
Chang, Chi-Yang
El-Omar, Emad M
Wu, Chun-Ying
Wu, Jeng-Yih
Tai, Chi-Ming
Lee, Ching-Tai
Wang, Wen-Lun
Abstract
Levofloxacin-based therapy or bismuth-based quadruple therapy are the recommended second-line regimens for Helicobacter pylori eradication after failure of clarithromycin-based therapy. However, resistance to levofloxacin has increased in the past decade. Furthermore, little is known about the long-term effects of H pylori eradication on the antibiotic resistome. In this study, we compared these second-line eradication therapies for efficacy, tolerability, and short-term and long-term effects on the gut microbiota, antibiotic resistome, and metabolic parameters.
SDGs
Type
journal article